AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Calcium release-activated calcium channel protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96D31

UPID:

CRCM1_HUMAN

Alternative names:

Protein orai-1; Transmembrane protein 142A

Alternative UPACC:

Q96D31; Q3MHV3; Q6DHX2; Q96BP7; Q96K71

Background:

Calcium release-activated calcium channel protein 1, also known as Protein orai-1 and Transmembrane protein 142A, plays a crucial role in mediating Ca(2+) influx following the depletion of intracellular Ca(2+) stores. This process is activated by the Ca(2+) sensor, STIM1, and is essential for various cellular functions, including the immune response and milk secretion in mammary epithelial cells.

Therapeutic significance:

The protein's involvement in Immunodeficiency 9 and Myopathy, tubular aggregate, 2, underscores its potential as a target for therapeutic intervention. These diseases, resulting from gene variants affecting the protein, highlight its critical role in immune function and muscle pathology. Exploring therapeutic strategies targeting this protein could lead to significant advancements in treating these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.